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Abstract
Background: A novel pathway incorporating faecal immunochemical testing (FIT) for rapid colorectal cancer diagnosis (RCCD)
was introduced in 2017. This paper reports on the service evaluation after 2 years of pathway implementation.
Methods: The RCCD protocol was based on FIT, blood results and symptoms to stratify adult patients in primary care. Two-week-
wait (2WW) investigation was indicated for patients with rectal bleeding, rectal mass and faecal haemoglobin (fHb) level of 10 mg Hb/
g faeces or above or 4 mg Hb/g faeces or more in the presence of anaemia, low ferritin or thrombocytosis, in all other symptom groups.
Patients with 100 mg Hb/g faeces or above had expedited investigation . A retrospective audit of colorectal cancer detected between
2017 and 2019 was conducted, fHb thresholds were reviewed and critically assessed for cancer diagnoses.
Results: In 2 years, 14788 FIT tests were dispatched with 13361 (90.4 per cent) completed returns. Overall, fHb was less than 4 mg Hb/g
faeces in 9208 results (68.9 per cent), 4–9.9 mg Hb/g in 1583 (11.8 per cent), 10–99.9 mg Hb/g in 1850 (13.8 per cent) and 100 mg Hb/g faeces
or above in 720 (5.4 per cent). During follow-up (median 10.4 months), 227 colorectal cancers were diagnosed. The cancer detection
rate was 0.1 per cent in patients with fHb below 4 mg Hb/g faeces, 0.6 per cent in those with fHb 4–9.9 mg Hb/g faeces, 3.3 per cent for
fHb 10–99.9 mg Hb/g faeces and 20.7 per cent for fHb 100 mg Hb/g faeces or above. The detection rate in the cohort with 10–19.9 mg Hb/g
faeces was 1.4 per cent, below the National Institute for Health and Care Excellence threshold for urgent referral. The colorectal can-
cer rate in patients with fHb below 20 mg Hb/g faeces was less than 0.3 per cent.
Conclusion: Use of FIT to "rule out" urgent referral from primary care misses a small number of cases. The threshold for referral may
be adjusted with blood results to improve stratification .
Introduction
Colorectal cancer is a common cancer diagnosis with over 40 000
new diagnoses each year, and is the second commonest cause of
cancer death in the UK1. Improving outcomes remains a key
healthcare policy aim2. Current criteria for urgent referral to sec-
ondary care are largely based on age and symptoms3, but the UK
bowel cancer screening programme (BCSP) has demonstrated
that colorectal cancer, and particularly in its early stage, is often
asymptomatic4. Faecal immunochemical testing (FIT) has
replaced guaiac-based faecal occult blood testing in the screening
programme across the UK. The thresholds for positivity in the
screening programme in England (120 mg haemoglobin (Hb)/g
faeces) and Wales (150 mg Hb/g faeces) are higher (less sensitive)
than those in Scotland (80 mg Hb/g faeces or above) and many
other countries around the world, and have been chosen to
mitigate the demand on overburdened diagnostic capacity in the
NHS5.
FIT has been shown to have value in patients with symp-
toms6–15, and in 2015 National Institute for Health and Care
Excellence (NICE) guidance recommended testing for occult blood
in faeces in low-risk patients3, and subsequently recommended a
threshold of 10 mg Hb/g faeces specifically in this context16.
In September 2016, a locally commissioned year-long pilot of
FIT in the 2-week-wait (2WW) population (excluding those with
rectal bleeding) was introduced, and demonstrated clear stratifi-
cation value in all symptom groups judged to be ‘high risk’ by lo-
cal primary care colleagues9. The value of simple measures such
as stratification of anaemia17–19 and thrombocytosis20,21 from a
full blood count (FBC) has been also confirmed in the same local
population. In November 2017, a rapid colorectal cancer
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diagnosis (RCCD) pathway incorporating direct general practi-
tioner (GP) access to FIT and the use of FIT, FBC and ferritin
results for ‘rule in’, ‘rule out’ and ‘first test’ selection in secondary
care was introduced11. This study aimed to evaluate the colorec-
tal cancer diagnoses from the first 2 years of this pathway, strati-
fied by FIT level22.
Methods
Rapid colorectal cancer diagnosis pathway
This local pathway was designed to incorporate FIT as a triage
tool for all referral criteria in adult patients of any age, except
those with rectal bleeding and rectal mass, as described else-
where11,22, presenting to local GP practices within the authors’
catchment area. GPs were able to request FIT (and blood tests)
independently and to act on the result, or, if clinical suspicion
was high, they could submit an RCCD referral form contempora-
neously. In the latter pathway, the form was held for 12 working
days in a ‘window’ and the 62-day clock started only either on
receipt of FIT (and blood) results or on expiry of the window. The
outcomes from this pathway have been evaluated prospectively,
and in June 2019 the window was no longer required after local
agreement that GPs were familiar with the pathway and contem-
poraneous audit data supported this change (Appendix S1).
The pathway was commissioned locally to allow direct access
to FIT for local GPs, and all four local clinical commissioning
groups (CCGs) (Nottingham City, Nottingham North and East,
Nottingham West and Rushcliffe) approved and jointly funded
the pathway. The cost of each faecal immunochemical test was
agreed as £17.50 (approximately e20) per sample to CCGs; this
included postage, analysis and administration costs.
Faecal immunochemical testing requests and
testing
FIT requests in primary care were made on an electronic request
system (ICE) that also prompted requests for blood tests, where
indicated. Results were notified on the same electronic system
with text guidance on how to interpret results and subsequent
actions. An electronic guidance system F12 (SystmOne; The
Phoenix Partnership, Leeds, UK) was also used to guide GPs on
the use of FIT and the new pathway in practices that used this
system, with direct links to the relevant referral form where ap-
propriate. FIT dispatch and return were entirely postal, and kits
were analysed according to the manufacturer’s protocols as de-
scribed elsewhere by an accredited BCSP hub laboratory
(Appendix S2)9,11,22. The OC-SensorTM platform (Eiken Chemical,
Tokyo, Japan) was used as described previously9.
Patients referred with a rectal mass were not subject to FIT,
but were seen in a one-stop flexible sigmoidoscopy clinic.
Patients with rectal bleeding, no other symptoms and no anae-
mia were also seen in a one-stop clinic, as well as some patients
with rectal bleeding deemed unlikely to be fit for colonoscopy at
straight-to-test (STT) vetting of referrals23. Patients diagnosed
with cancer in this one-stop pathway could have CT colonogra-
phy as part of their staging to exclude synchronous lesions, if
appropriate. This pathway has traditionally excluded rectal
bleeding because the colorectal cancer detection rate approaches
10 per cent in this group locally, and the use of flexible sigmoid-
oscopy mitigates colonoscopy demand.
FIT, FBC and ferritin (or iron studies) were mandated for
all other referrals, irrespective of symptoms or age, by local
agreement with partners in primary care.
‘Rule in’
Between November 2017 and June 2019, patients with a FIT result
of 150 mg Hb/g faeces or above were considered ‘high risk’ posi-
tive, and the result was notified directly by BCSP to the
Nottingham Colorectal Service STT team, as well as to the GP,
irrespective of whether an RCCD form had been submitted.
The STT team contacted these patients directly for vetting and
appropriate investigation on a ‘rapid’ pathway, according to local
protocols. This threshold was lowered to 100 mg Hb/g faeces
or above in June 2019 as prospective evaluation demonstrated
significant colorectal cancer detection rates at this threshold.
Patients with a faecal Hb (fHb) level of 10 mg Hb/g faeces or above
or 4 mg Hb/g faeces or above in the presence of anaemia, low
ferritin or thrombocytosis were also considered positive, and
were investigated on a 2WW pathway.
‘Rule out’
Patients with a FIT result below 4 mg Hb/g faeces were considered
to have a ‘negative’ FIT test result and to be at low risk for colo-
rectal cancer. Patients with a FIT result of 4 mg Hb/g faeces or
above but below 10 mg Hb/g faeces were also considered to have a
negative result if their Hb level was normal (at least 130 g/l in
men and 120 g/l in women), ferritin concentration was normal,
and platelet count was less than 400  109/l). GPs were advised
that patients with negative FIT tests had a low risk of colorectal
cancer, and management options were to consider an alternative
urgent pathway, routine referral, or repeat FIT.
Cohort and data collection
All patients who were subject to a FIT request between
7 November 2017 and 5 November 2019 were logged prospectively
in the BCSP hub to ensure clinical governance of this novel
pathway. All patients referred to the Nottingham Colorectal
Service STT team on an RCCD form between these dates were
logged prospectively in NUhCLEUS database (a locally created
software programme), which supports the STT pathway. Cancer
Outcomes and Services Data sets (COSD) were used to evaluate
diagnoses of colorectal cancer recorded using ICD codes C18-C20
(excluding C18.1) with a censor date of 31 December 2019.
Nottingham University Hospitals NHS Trust data, electronic pa-
tient records, and NUhCLEUS data were used for cross-checking
and validation of diagnosis data. Cancer diagnoses were related
to any previous patient episodes that started from a FIT result,
and are presented in that context. Further details of patients who
had repeat FIT testing are presented in Fig. 1 and Appendix S3.
Statistical analysis
Histograms were used to check for normal distribution.
Comparisons were made between continuous variables using
Student’s t test and ANOVA if normally distributed, with Tukey’s
multiple comparison test for multiple groups. Categorical data
were summarized using frequencies and percentages.
Comparisons were made between categorical data using v2 tests.
All statistical analyses were performed using GraphPad PrismVR
(GraphPad Software, San Diego, CA, USA). Tests of significance
were considered significant when P < 0.050 was obtained.
Data were segmented and analysed by fHb according to the
cut-offs used during a pilot study9 and subsequent iterations of
pathway, as described above and elsewhwere11,18. For the pri-
mary analyses, fHb below 4, 4–9.9, 10–99.9 and 100 mg Hb/g faeces
or above were used. The latter group was further segmented into
100–149.9 and 150 mg Hb/g faeces or more (original cut-off for
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high-risk positivity). Further segmentation for subanalysis of
results between 10 and 99.9 mg Hb/g faeces was chosen empiri-
cally as follows: 10–19.9, 20–39.9, 40–59.9, 60–79.9 and 80–99.9 mg
Hb/g faeces.
Results
Faecal immunochemical test requests and results
In total 15 589 FIT requests were made during the evaluation
period (Fig. 1). Some 564 requests (3.6 per cent) were rejected
as clinical details mentioned rectal bleeding as a symptom.
There were 162 duplicate requests (1.0 per cent) and 75 requests
(0.5 per cent) were declined for other reasons. A total of 14788
kits were dispatched, and 13395 kits were returned within
14 days (90.6 per cent), 34 kits were spoiled on return or not suit-
able for analysis (0.2 per cent).
Overall, 13361 FIT results were available, of which 9208 (68.9
per cent) were less than 4 mg Hb/g faeces, 1583 (11.8 per cent) were
4–9.9 mg Hb/g faeces, 1850 (13.8 per cent) were 10–99.9 mg Hb/g fae-
ces, and 720 (5.4 per cent) were 100 mg Hb/g faeces or above. Table 1
shows the patient demographic characteristics in each subgroup.
The majority (67.8 per cent) of FIT occurred in symptomatic
patients over the age of 60 years who met the current NICE guid-
ance for referral3. Some 505 FIT results (3.8 per cent) were from
patients under the age of 40 years and 81.6 per cent (412 of 505)
yielded fHb below 4 mg Hb/g faeces. The mean age of patients with
lower levels of fHb was significantly lower than that for the higher
strata of fHb (P< 0.0001, ANOVA; P< 0.01, Tukey’s multiple
comparison test). The cohort diagnosed with colorectal cancer was
significantly older than those without (P< 0.001, unpaired t test).
There were significantly more men in the cohort with fHb 100 mg
Hb/g faeces or above compared with those with lower fHb levels
(53.1 versus 43.5 per cent respectively; v2 ¼ 25.2, P< 0.001), and
also in patients diagnosed with colorectal cancer compared with
those without that diagnosis (59.5 versus 43.7 per cent; v2 ¼ 22.4,
P< 0.001).
Colorectal cancer diagnoses after faecal
immunochemical testing
The median follow-up in this cohort was 10.4 (i.q.r. 5.7–16.3)
months (Table 1). In total, 227 colorectal cancers were diagnosed
after FIT (1.7 per cent of the 13 361 tests performed). Eight
cancers were diagnosed in 8920 patients (0.1 per cent) after a
FIT result with fHb below 4 mg Hb/g faeces during follow-up,
10 cancers in 1568 patients (0.6 per cent) with fHb 4–9.9 mg Hb/g
faeces, 61 in 1840 patients (3.3 per cent) with fHb 10–99.9 mg Hb/g
faeces, and 148 cancers (20.7 per cent) in 714 patients with fHb
100 mg Hb/g faeces or above. The known colorectal cancer detec-
tion rates were significantly lower in the group with fHb below
4 mg Hb/g faeces than in the rest of the cohort (0.1 versus 5.3 per
cent respectively; v2 ¼ 449.7, P< 0.001) and in the group with fHb
below 10 mg Hb/g faeces (0.2 versus 8.2 per cent respectively;
v2 ¼ 770.8, P< 0.001). The known colorectal cancer detection rate
was significantly higher in the cohort with fHb 100 mg Hb/g faeces
or above, compared to less those with fHb less than 100 mg Hb/g
faeces (20.7 per cent versus 0.6 per cent; v2 ¼ 1592.4, P< 0.001).
Three diagnoses of colorectal cancer were related to repeat FIT in
FIT requests
n = 15 589
Requests declined n = 799
   Rectal bleeding n = 564
   From Derbyshire n = 52
   Duplicate request n = 162
   Other n = 23
Kit not returned n = 1393
Kit damaged/not analysable n = 34
Kits disptached
n = 14 788
Results obtained
n = 13 361
FIT< 4 mg hb/g faeces
9208 results
8921 patients
8 cancers (0.1%)
FIT 4– 9.9 mg hb/g faeces
1583 results
1568 patients
10 cancers (0.6%)
FIT 10– 99.9 mg hb/g faeces
1850 results
1829 patients
65 cancers (3.6%)
FIT ≥100 mg hb/g faeces
720 results
714 patients
148 cancers (20.7%)
FIT 100–149.9 mg hb/g faeces
167 patients
20 cancers (12.0%)
FIT ≥150mg hb/g faeces
547 patients
128 cancers (23.4%)
Fig. 1 Flow diagram of patients with faecal immunochemical testing requests from referral to colorectal cancer diagnosis
Numbers of patients lower than number of results in each stratum reflects repeat tests within one stratum. For additional data see Appendix S3. FIT, faecal
immunochemical testing; Hb, haemoglobin.
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229 patients with sequential fHb results in different strata
(Appendix S3).
Overall, 86.8 per cent (197 of 227) of colorectal cancers were di-
agnosed in patients over the age of 60 years. One patient aged un-
der 40 years was diagnosed with cancer with a fHb result of 100
mg Hb/g faeces or above, and 29 cancers were diagnosed in those
aged 40–59 years.
Colorectal cancer diagnoses after a negative test
result
Eight of 227 CRCs (3.5 per cent) were diagnosed after a fHb
reported as less than 4 mg Hb/g faeces (Table S1). These patients
were identified via referral through other pathways: three had CT
arranged by the upper gastrointestinal team, two were seen by
the medical gastroenterology team, two were diagnosed in rou-
tine colorectal clinics, and one presented as an emergency with
acute bowel obstruction. The median time from a negative FIT re-
sult to colorectal cancer diagnosis was 41.5 (i.q.r. 31–72.3) days.
One sample was analysed after 17 days, and the patient should
have had repeat FIT due to risk of a false-negative result24. In the
population with fHb 4–9.9 mg Hb/g faeces, all patients but one sat-
isfied the Nottingham protocol whereby an abnormal blood pa-
rameter (anaemia, thrombocytosis or low ferritin (or iron))
reduces the threshold to investigate to 4 mg Hb/g faeces (Table S1).
The other patient had an abnormally high ferritin level but was
considered ‘negative’ according to local protocol at the time of
testing.
Blood results and palpable rectal mass
Detection rates for different strata of fHb within the range
10–99.9 mg Hb/g faeces are shown in Table 2. The colorectal cancer
detection rate in the group with fHb 10–19.9 mg Hb/g faeces was
1.4 per cent, and was below the NICE 3 per cent threshold for ur-
gent referral. These patients were all eligible for 2WW referral
and investigation in the local protocol. Eight of 10 colorectal can-
cers detected in this stratum had abnormal blood parameters or
abnormal digital rectal examination before referral (Table S1).
Forty-seven of 61 patients with cancer (77 per cent) detected after
fHb result of 10–99.9 mg Hb/g faeces had one or more abnormal
blood test results or a palpable rectal mass (latter not mentioned
on referral from primary care). Six cancers were detected in 11
194 patients with fHb below 20 mg Hb/g faeces in whom there was
no evidence of abnormal blood results or palpable rectal mass.
Discussion
This is a large English data set on primary care access to FIT in
symptomatic patients for all symptoms and all age groups. In
previous studies, a colorectal cancer diagnosis rate of 0.2 per cent
in patients undergoing 2WW investigation with fHb below 4 mg
Hb/g faeces was documented9,11,22. Data from Scotland suggest a
similar ‘miss rate’ with longer follow-up in patients with unquan-
tifiable fHb levels on a different manufacturer’s platform10. The
colorectal cancer diagnosis rate of 0.1 per cent after a ‘negative’
FIT test (as per local definition) in this population is consistent
with these data, and appears well below the NICE threshold of 3
per cent, despite including the NG12 ‘high risk’ population3.
Other strengths of this study include a large data set with optimal
return rates and a ‘real-world’ analysis of FIT usage in a clinical
setting. Use of a prospectively recorded database to log cancer di-
agnoses validates the accuracy of the retrospective study.
In evaluating this pathway, it is important to stress that FIT
should not be compared to colonoscopy, because, in the UK and
many other countries, GPs do not have direct access to colonos-
copy. Instead, 2WW pathways that use FIT in primary care
should be compared with those that do not. Indeed, the ‘miss
rate’ of age- and symptom-based criteria in primary care (the
number of cancers detected in symptomatic patients after rou-
tine referral) was historically around 50 per cent on average21,
and even a standard investigation such as colonoscopy is known
to miss diagnoses of colorectal cancer25.
Overall, 5588 patients aged 60 years or more with fHb below 4
mg Hb/g faeces were tested by GPs. This would have equated to
more than 230 additional referrals per month over 2 years (if FIT
had not been used for ‘rule out’) to detect eight colorectal can-
cers.
However, this methodology does not identify patients diag-
nosed with colorectal cancer at other trusts, which is a relative
weakness. Concomitant analysis across the Cancer Alliance is
ongoing, and analysis of East Midlands Cancer Network data has
not yet demonstrated additional cases of ‘post- negative FIT colo-
rectal cancer’, although this scenario may arise. In addition, most
patients have not been investigated after a ‘negative’ FIT result,
Table 1 Demographics of all patients with a faecal immunochemical test result and colorectal cancer diagnoses stratified by faecal
haemoglobin and age
FIT stratum
(mg Hb/g faeces)
Median follow-up
(months)
Patients with
FIT results
Sex
ratio (M : F)
Age (years)
Mean(s.e.m.)  49† 50–59†  60†,‡
Total 10.4 (5.7–16.3) 13 042 5740 : 7302 66.3(0.2) 1658 (12.7) 2546 (19.5) 8838 (67.8)
Total cancers diagnosed 227 (1.7) 135 : 92§ 74.1(1.2)¶
< 4 10.6 (5.8–16.5) 8920 3850 : 5070 64.5(0.1)¶ 1329 (14.9) 2003 (22.5) 5588 (62.6)
Cancers diagnosed 8 (0.1)§ 6 : 2 77.4(3.1) 0 (0) 0 (0) 8 (0.1)
4–9.9 10.6 (5.0–15.0) 1568 656 : 912 69.0(0.3)¶ 146 (9.3) 224 (14.3) 1198 (76.4)
Cancers diagnosed 10 (0.6)§ 5 : 5 75.0(3.6) 1 (0.7) 0 (0) 9 (0.7)
10–99.9 9.9 (5.7–15.8) 1840 855 : 985 71.4(0.3)¶ 129 (7.0) 234 (12.7) 1477 (80.3)
Cancers diagnosed 61 (3.3)§ 34 : 27 74.6(1.4) 1 (0.8) 7 (3.0) 53 (3.6)
 100 10.3 (5.9–16.2) 714 379 : 335§ 71.5(0.5)¶ 54 (7.6) 85 (11.9) 575 (80.5)
Cancers diagnosed 148 (20.7)§ 90 : 58 73.7(0.9) 7(13) 14 (16) 127 (22.1)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.); †percentage values are of stratum. ‡Patients aged 60 years or more
with symptoms commonly eligible for urgent referral according to National Institute for Health and Care Excellence guidance3. FIT, faecal immunochemical test;
Hb, haemoglobin. §P < 0.001 (v2 tests comparing FIT strata by gender, and colorectal cancer diagnosis by gender); ¶P< 0.001 (ANOVA comparing patient age by FIT
strata).
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and some may yet present with colorectal cancer with ongoing
follow-up.
In this study, only nine cancers were diagnosed in patients un-
der the age of 50 years, and unsurprisingly the majority had fHb
of 100 mg Hb/g faeces or above. The recommendation16 of a fHb
threshold of 10 mg Hb/g faeces for ‘low risk’ patients appears
questionable in this context. A threshold as low as 4 mg Hb/g fae-
ces in patients with anaemia, low ferritin and thrombocytosis
was driven by concern around the use of FIT in ‘high risk’
patients, but is vindicated by the detection of nine such patients
with colorectal cancer in the cohort with fHb below 10 mg Hb/g
faeces. Interestingly, these data suggest a similar principle may
be applicable between 10 and 19.9 mg Hb/g faeces, and perhaps at
even higher levels. The utility of anaemia19 and thrombocytosis21
in the local 2WW pathway have been evaluated previously, but
not that of ferritin. The protocol has hitherto mandated investi-
gation only when ferritin level is low. However, studies have sug-
gested that ferritin may have value when the level is abnormally
high26, and thus there may be value in using high ferritin to im-
prove the sensitivity and specificity of the symptomatic pathway.
In the present cohort, only one additional cancer would have
been missed if the threshold had been 20 mg Hb/g faeces for
patients with normal rectal examination, FBC and ferritin. FIT is
a stratification tool, and appears to be most useful when
combined with other objective measures. The FAST (Faecal hae-
moglobin, Age and Sex Test) score27, combining FIT with age and
sex, could be improved28, and performance characteristics of
such scoring systems might increase if FIT were combined with
FBC, ferritin and a digital rectal examination. These four Fs
appear likely to have greatest combined value as the level of fHb
declines towards undetectable.
The use of FIT has been introduced in the English BCSP with a
threshold of 120 mg Hb/g faeces. This raises a number of interest-
ing issues in relation to the training, accreditation, and workload
of endoscopists. The challenge to reduce the FIT threshold or the
screening age in England might be aided by the use of higher FIT
thresholds, alongside blood tests, in symptomatic patients as
greater diagnostic capacity is freed up. An alternative solution
may be to invite screened patients with a FIT result below
120 mg Hb/g faeces to attend their GP for FBC and ferritin testing,
and to lower the threshold when such parameters are abnormal.
Ultimately, raising symptomatic thresholds and lowering BCSP
thresholds may help to yield more coherent and consistent use of
FIT in all parts of the population.
Both symptomatic and asymptomatic pathways face unprece-
dented circumstances in the UK in relation to the coronavirus
pandemic. UK diagnostic services that were overstretched before
the pandemic will doubtless struggle to cope with a backlog for
many months afterwards. Accordingly, FIT results and other
objective measures such as blood results should be used to
prioritize those individuals most likely to benefit from urgent
investigation (Appendix S4).
Finally, other large service evaluation studies10,14 have now
demonstrated similar results to those from the present data set,
and the recently published NICE FIT study15 adds high-volume
multicentre research data to this consensus. No test is perfect,
but there is now a high volume of data to demonstrate that FIT
adds significant value to symptoms alone in aiding the decision
to refer.
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